


PR-104 sodium

Cat. No.:	HY-16406
CAS No.:	851627-80-0
Molecular Formula:	C ₁₄ H ₁₉ BrN ₄ NaO ₁₂ PS
Molecular Weight:	601.25
Target:	DNA Alkylator/Crosslinker
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PR-104 (sodium) is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104 (sodium), as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A ^[1] .								
In Vitro	PR-104 (sodium) (80 μM; 1 hour; SiHa cells) shows greater suppression of radiation-induced DNA single-strand breaks under hypoxic than aerobic conditions. PR-104 (sodium) (100 μM; 1 hour; SiHa cells) results in phosphorylation of Ser139 of histone H2AX (gH2AX). PR-104 (sodium) (0.266 mmol/kg; 18 h; SiHa cells) shows activity against hypoxic cells after irradiation. PR-104 (sodium) varies in potency between cell lines, with the lowest IC ₅₀ (0.51 μmol/L) in H460 cells and highest (7.3 μmol/L) in PC3 prostate cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	PR-104 (sodium) (0.56 mmol/kg; i.v. or i.p.; 0~2 hours) makes the plasma area under the curve. PR-104 (sodium) (0.23 mmol/kg; i.p.; 100 days) shows antitumor activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>CD-1nu/nu mice</td> </tr> <tr> <td>Dosage:</td> <td>0.56 mmol/kg (Pharmacokinetics Analysis)</td> </tr> <tr> <td>Administration:</td> <td>i.v. or i.p.</td> </tr> <tr> <td>Result:</td> <td>The plasma area under the curve.</td> </tr> </table>	Animal Model:	CD-1nu/nu mice	Dosage:	0.56 mmol/kg (Pharmacokinetics Analysis)	Administration:	i.v. or i.p.	Result:	The plasma area under the curve.
Animal Model:	CD-1nu/nu mice								
Dosage:	0.56 mmol/kg (Pharmacokinetics Analysis)								
Administration:	i.v. or i.p.								
Result:	The plasma area under the curve.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>CD1-Foxn1nu mice</td> </tr> <tr> <td>Dosage:</td> <td>0.23 mmol/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Showed antitumor activity.</td> </tr> </table>	Animal Model:	CD1-Foxn1nu mice	Dosage:	0.23 mmol/kg	Administration:	i.p.	Result:	Showed antitumor activity.
Animal Model:	CD1-Foxn1nu mice								
Dosage:	0.23 mmol/kg								
Administration:	i.p.								
Result:	Showed antitumor activity.								

REFERENCES

[1]. Patterson AV, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922-3932.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA